Clinical trial launches for inhaled insulin, digital diabetes platform
MannKind Coroporation and One Drop announced the launch of a collaborative study of inhaled insulin and an integrated diabetes management platform, according to a press release from the companies.
The study will randomly assign participants with type 2 diabetes to either inhaled rapid-acting mealtime insulin (Afrezza, MannKind) with One Drop’s management system, consisting of a mobile app, a meter, test strips and coaching services, or to One Drop’s system alone.
Endpoints will include HbA1c, quality of life, self-care and treatment satisfaction.
“This study is intended to evaluate whether combining a solutions-oriented digital disease management platform like One Drop with an innovative drug like Afrezza will provide patients with an improved ability to manage their diabetes.,” Raymond Urbanski, MD, PhD, chief medical officer of MannKind Corporation, said in the release.